Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine

[1]  A. Vickers.  Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. , 2021, European urology.

[2]  A. Tewari,et al.  Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion , 2020, International journal of urology : official journal of the Japanese Urological Association.

[3]  P. Scardino,et al.  A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy , 2020, British Journal of Cancer.

[4]  M. Cooperberg,et al.  Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. , 2020, European urology.

[5]  P. Choyke,et al.  MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. , 2020, The New England journal of medicine.

[6]  T. H. van der Kwast,et al.  A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.

[7]  K. D. Sørensen,et al.  Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine. , 2019, Clinical chemistry.

[8]  A. Vickers,et al.  Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups. , 2018, European urology.

[9]  I. Balslev,et al.  Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men , 2018, JAMA network open.

[10]  M. Borre,et al.  Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study , 2018, Scandinavian journal of urology.

[11]  K. D. Sørensen,et al.  Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine. , 2017, European urology focus.

[12]  H. G. van der Poel,et al.  What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. , 2017, European urology.

[13]  F. Hamdy,et al.  Properties of the 4‐Kallikrein Panel Outside the Diagnostic Gray Zone: Meta‐Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above , 2017, The Journal of urology.

[14]  P. Scardino,et al.  Predictive Performance evaluation Clinical Performance of the 4 Kscore Test to Predict High-grade Prostate Cancer at Biopsy : A Meta-analysis of US and European Clinical Validation Study Results , 2017 .

[15]  P. Scardino,et al.  Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. , 2017, Reviews in urology.

[16]  J. Fütterer,et al.  Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. , 2015, European urology.

[17]  John W. Scott,et al.  A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. , 2015, European urology.

[18]  P. Scardino,et al.  Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study , 2015, Journal of the National Cancer Institute.

[19]  D. Parekh,et al.  Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. , 2015, Reviews in urology.

[20]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[21]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[22]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[23]  P. Scardino,et al.  Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate‐specific antigen , 2010, Cancer.

[24]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[25]  Andrew J Vickers,et al.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden , 2008, BMC medicine.

[26]  H. Lilja,et al.  Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein 2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(ab')(2) Fragments. , 2006 .

[27]  H. Lilja,et al.  Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. , 2006, Analytical chemistry.

[28]  Kim Pettersson,et al.  Development of sensitive immunoassays for free and total human glandular kallikrein 2. , 2004, Clinical chemistry.